This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck Sells Eye Products to Japan's Santen

NEW YORK (The Deal) -- Merck (MRK - Get Report) is selling its ophthalmology product portfolio for Japan and other markets in the Asia Pacific region and Europe to Japan's Santen Pharmaceutical.

Osaka-based Santen is making an up-front payment of about $600 million with more to come based on sales milestones, Merck said Tuesday.

Santen is a specialty pharma with a portfolio of in the ophthalmic and anti-rheumatic fields. It is No. 1 in market share for prescription ophthalmic pharmaceuticals in Japan.

"This transaction strengthens Santen's lineup of glaucoma products, significantly expands Santen's footprint in Japan, Asia and Europe and is an important step in achieving its long-term corporate vision to become a specialized pharmaceutical company with a global presence by 2010," Akira Kurokawa, president and CEO, said in a statement.

Must Read: Pershing Square Eyes Nonbinding Vote on Allergan Bid

Products within the agreement had annual sales of about $400 million. They include ophthalmic solutions Cosopt, Cosopt PF (preservative-free), Trusopt, Trusopt PF, Timoptic, Timoptic PF, Timoptic XE, Saflutan and Taptiqom, a product in development.

Santen also agreed to purchase supplies of the products from Merck for two to five years, the companies said.

"The decision to divest our ophthalmics business is part of our ongoing strategy to sharpen our commercial focus and improve our operational effectiveness," Merck's Jay Galeota, president, Hospital and Specialty Care, said in a statement.

Whitehouse Station, N.J.-based Merck, known as MSD outside the U.S. and Canada, will continue to sell the products in Africa, Australia, Canada, Latin America, the Middle East and other markets.

Merck recently divested its ophthalmology business in the U.S. to Lake Forest, Ill.'s Akorn Pharmaceuticals Inc.

The Santen deal is expected to close within the next few months in most markets. It is subject to antitrust clearance in Japan and other closing conditions in specific markets or regions affected.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $54.84 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs